Leinco Technologies

Anti-Human CD22 - DyLight® 650

Product Code:
 
LEI-C1956
Product Group:
 
Primary Antibodies
Host Type:
 
Mouse
Antibody Isotype:
 
IgG1
Antibody Clonality:
 
Monoclonal
Antibody Clone:
 
RFB-4
Regulatory Status:
 
RUO
Target Species:
 
Human
Application:
 
Flow Cytometry
Shipping:
 
2-8°C
Storage:
 
This DyLight® 650 conjugate is stable when stored at 2-8°C. Do not freeze.
 

No additional charges, what you see is what you pay! *

CodeSizePrice
LEI-C1956-50ug50 ug£159.00
Quantity:
LEI-C1956-100ug100 ug£211.00
Quantity:
LEI-C1956-200ug200 ug£291.00
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: US.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Related Products
  • Show All

Further Information

Antigen Distribution:
The CD22 antigen is expressed on >90% of peripheral blood B-cells.1 This antigen is not present on T-cells, monocytes or macrophages. CD22 is expressed on most peripheral B-cell lymphomas and leukemias including hairy cell leukemia, but not on the immature bone marrow type of leukemia.
Concentration:
0.2 mg/ml
Conjugate/Tag/Label:
DyLight® 650
Format:
This DyLight® 650 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Formulation:
This DyLight® 650 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Immunogen:
Purified Recombinant Human CD22 (>98%)
Long Description:
Cluster of differentiation 22 also known as CD22 is a B-cell-restricted transmembrane protein, which acts as a negative regulator of B-cell signalling. CD22 also has lectin-like adhesive properties.1 CD22 is a good target to shorten the time required for Ab production, thereby augmenting host defense against acute infectious diseases as "universal vaccination."2
NCBI Gene:
933
Target:
CD22

References

1. Crocker PR et al. (2000) Immunol. 101: 342 2. Tsubata T et al. (2008) J Immunol. 180: 907